- Eyenovia ( NASDAQ: EYEN ) on Tuesday has named its operations chief Michael Rowe as the ophthalmic pharma's new chief executive officer, effective Aug. 1, 2022.
- The announcement comes after the nationwide search of a candidate to succeed CEO Sean Ianchulev, who announced resignation last month to rather transition into the role of Eyenovia's non-executive chairman.
- The company told Rowe will also be appointed to its Board, increasing seats to nine.
- Rowe has served as Eyenovia's COO since Jan. 2021 following his joining in Jul. 2018. More recently, he was with Aerie Pharmaceuticals and has earlier spent 12 years at Allergan, founding the health economics department as well as liaison with Senju Pharmaceuticals (a current shareholder and licensee of Eyenovia) and was instrumental in the successful launch of multiple glaucoma products in the Japanese market, report.
For further details see:
Eyenovia names Michael Rowe as new CEO